(Q51020785)

English

Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma.

scientific article published on 12 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

Raphaël Porcher

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

11

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

author name string

S Mourah

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

M Battistella

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

D Kerob

4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

B Guillot

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

T Jouary

6

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

F Agbalika

7

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

F Morinet

8

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

V Furlan

9

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

H M Teisserenc

10

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

C Lebbé

12

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

language of work or name

0 references

publication date

12 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

173

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

1284-1287

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1111%2FBJD.13897

21 January 2018

Kaposi sarcoma in transplantation

1 reference

https://api.crossref.org/works/10.1111%2FBJD.13897

21 January 2018

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.13897

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FBJD.13897

21 January 2018

The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy

1 reference

https://api.crossref.org/works/10.1111%2FBJD.13897

21 January 2018

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJD.13897

21 January 2018

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FBJD.13897

21 January 2018

Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1111%2FBJD.13897

21 January 2018

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

1 reference

https://api.crossref.org/works/10.1111%2FBJD.13897

21 January 2018

Identifiers

10.1111/BJD.13897

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/25970141

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51020785&oldid=1267248397"